Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin Dosing for VTE Prevention in Trauma and Surgical Patients
NCT02342444Phase 4Recruiting
- Sponsor
- Oregon Health & Science University
- Start
- Feb 2014
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by Oregon Health & Science University. Primary endpoint: Thromboembolic events. Started Feb 2014; status: recruiting.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02342444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342444.